Gene Page: PPP2R3C
Summary ?
| GeneID | 55012 |
| Symbol | PPP2R3C |
| Synonyms | C14orf10|G4-1|G5pr |
| Description | protein phosphatase 2 regulatory subunit B'', gamma |
| Reference | MIM:615902|HGNC:HGNC:17485|Ensembl:ENSG00000092020|HPRD:12622|Vega:OTTHUMG00000140224 |
| Gene type | protein-coding |
| Map location | 14q13.2 |
| Pascal p-value | 1.531E-5 |
| Sherlock p-value | 0.746 |
| eGene | Caudate basal ganglia Cortex Frontal Cortex BA9 Hippocampus |
Gene in Data Sources
| Gene set name | Method of gene set | Description | Info |
|---|---|---|---|
| CV:PGCnp | Genome-wide Association Study | GWAS |
Section I. Genetics and epigenetics annotation
Section II. Transcriptome annotation
General gene expression (GTEx)
Gene expression of temporal and spatial changes (BrainSpan)
Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes the lower 25% and upper 25% of the expression distribution.
Top co-expressed genes in brain regions
| Top 10 positively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| GMIP | 0.95 | 0.93 |
| SEMA6C | 0.95 | 0.93 |
| PARP16 | 0.94 | 0.90 |
| JUP | 0.94 | 0.87 |
| ZNF509 | 0.94 | 0.90 |
| REC8 | 0.93 | 0.90 |
| SHF | 0.93 | 0.94 |
| DBN1 | 0.93 | 0.91 |
| GRAMD1A | 0.93 | 0.92 |
| MARCKSL1 | 0.93 | 0.88 |
| Top 10 negatively co-expressed genes | ||
| Gene | Pearson's Correlation | Spearman's Correlation |
| HLA-F | -0.76 | -0.77 |
| AIFM3 | -0.75 | -0.75 |
| C5orf53 | -0.74 | -0.73 |
| FBXO2 | -0.73 | -0.65 |
| ALDOC | -0.73 | -0.70 |
| AF347015.27 | -0.73 | -0.89 |
| S100B | -0.73 | -0.81 |
| AF347015.31 | -0.72 | -0.88 |
| CLU | -0.72 | -0.70 |
| MT-CO2 | -0.71 | -0.90 |
Section V. Pathway annotation
| Pathway name | Pathway size | # SZGR 2.0 genes in pathway | Info |
|---|---|---|---|
| RODRIGUES THYROID CARCINOMA POORLY DIFFERENTIATED UP | 633 | 376 | All SZGR 2.0 genes in this pathway |
| RODRIGUES THYROID CARCINOMA ANAPLASTIC UP | 722 | 443 | All SZGR 2.0 genes in this pathway |
| GRAESSMANN APOPTOSIS BY DOXORUBICIN DN | 1781 | 1082 | All SZGR 2.0 genes in this pathway |
| LOCKWOOD AMPLIFIED IN LUNG CANCER | 214 | 139 | All SZGR 2.0 genes in this pathway |
| BENPORATH NANOG TARGETS | 988 | 594 | All SZGR 2.0 genes in this pathway |
| BENPORATH SOX2 TARGETS | 734 | 436 | All SZGR 2.0 genes in this pathway |
| NOUZOVA TRETINOIN AND H4 ACETYLATION | 143 | 85 | All SZGR 2.0 genes in this pathway |
| KRIGE RESPONSE TO TOSEDOSTAT 6HR UP | 953 | 554 | All SZGR 2.0 genes in this pathway |
| KRIGE RESPONSE TO TOSEDOSTAT 24HR UP | 783 | 442 | All SZGR 2.0 genes in this pathway |
| SHEDDEN LUNG CANCER POOR SURVIVAL A6 | 456 | 285 | All SZGR 2.0 genes in this pathway |
| MEISSNER ES ICP WITH H3K4ME3 | 34 | 17 | All SZGR 2.0 genes in this pathway |
| MEISSNER NPC ICP WITH H3K4ME3 | 20 | 9 | All SZGR 2.0 genes in this pathway |
| MEISSNER BRAIN ICP WITH H3K4ME3 | 32 | 17 | All SZGR 2.0 genes in this pathway |
| BOYAULT LIVER CANCER SUBCLASS G3 UP | 188 | 121 | All SZGR 2.0 genes in this pathway |
| CHIANG LIVER CANCER SUBCLASS UNANNOTATED DN | 193 | 112 | All SZGR 2.0 genes in this pathway |
| MIKKELSEN ES ICP WITH H3K4ME3 | 718 | 401 | All SZGR 2.0 genes in this pathway |
| MIKKELSEN NPC ICP WITH H3K4ME3 | 445 | 257 | All SZGR 2.0 genes in this pathway |
| PILON KLF1 TARGETS DN | 1972 | 1213 | All SZGR 2.0 genes in this pathway |
| VANOEVELEN MYOGENESIS SIN3A TARGETS | 220 | 133 | All SZGR 2.0 genes in this pathway |